PeptidePedia The community reference

Information for Peptide harm reduction

Page information·measured at build time

Technical and provenance information about Peptide harm reduction. All figures on this page are measured from the emitted page rather than declared.

Basic information

Display titlePeptide harm reduction
Default sort keyPeptide harm reduction
NamespaceArticle (main)
Page kindConcept
Page length (source, bytes)4,800
Rendered word count558
Internal wiki links on the page22
Defined citations4
Top-level sections3
Subsections0
Tables1
Figures0
InfoboxYes — concept
Maintenance bannersNone
Indexing by robotsAllowed

Edit history

Page creatorHarmReductionHen
Date of page creation29 November 2024
Latest editorTierTwoTansy
Date of latest edit18 July 2026
Total number of edits39
Total number of distinct authors27
Minor edits10
Automated (bot) edits3
Recent number of edits (last 90 days)4
Talk page posts6

Principal authors

EditorEditsShareDeclared focus
CostPerMgCory410.3%access, cost and insurance
TierTwoTansy37.7%access, cost and insurance
PatientPanelPru37.7%access, cost and insurance
HarmReductionHen25.1%access, cost and insurance
ReaderRosalie25.1%access, cost and insurance
TrialsTabitha25.1%clinical trials and evidence appraisal
StubSorterBot25.1%categorisation and navigation
PBM_Perrin25.1%access, cost and insurance
CDMO_Caradoc12.6%peptide synthesis and supply chain
ExenatideEzra12.6%GLP-1 receptor agonists and related compounds
OffLabelOdile12.6%access, cost and insurance
FlowTrialFraser12.6%clinical trials and evidence appraisal

Category membership